Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | ALPL | P05186 | 1/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL320418 | 0.84 | PTGDR2 (0.66) | PKMSMN1; SMN2TSHRPTGDR2TDP1 | |
| SCHEMBL1948781 | 0.83 | SMN1; SMN2 (0.58) | SMN1; SMN2TSHRGAANPC1RAB9A | |
| SCHEMBL11555227 | 0.83 | L3MBTL1 (0.57) | SMN1; SMN2TSHRGAANPC1RAB9A | |
| SCHEMBL14066214 | 0.83 | PTGDR2 (0.60) | PKMSMN1; SMN2TSHRPTGDR2TDP1 | |
| SCHEMBL2113005 | 0.82 | PTGDR2 (0.64) | SMN1; SMN2TSHRGAANPC1RAB9A | |
| SCHEMBL1615073 | 0.82 | PKM (0.70) | PKMSMN1; SMN2TSHRNPC1RAB9A | |
| SCHEMBL4975454 | 0.81 | PKM (0.64) | PKMSMN1; SMN2TSHRPTGDR2MEN1 | |
| SCHEMBL2717225 | 0.81 | PTGDR2 (0.62) | PKMSMN1; SMN2TSHRPTGDR2TDP1 | |
| SCHEMBL5502944 | 0.81 | PKM (0.68) | PKMTSHRPTGDR2TDP1 | |
| SCHEMBL12145826 | 0.80 | SMN1; SMN2 (0.55) | SMN1; SMN2TSHRGAANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1550662-B1 | ADENINE COMPOUND AND USE THEREOF | DAINIPPON SUMITOMO PHARMA CO (JP) | 2012-07-04 | — | — | EP | disclosed |
| EP-2396295-A1 | PHENOXY ACETIC ACID DERIVATIVES | Merck Serono S.A. (CH) | 2011-12-21 | — | — | EP | disclosed |
| WO-2010092043-A1 | PHENOXY ACETIC ACID DERIVATIVES | MERCK SERONO S.A. (CH) | 2010-08-19 | — | — | WO | disclosed |
| US-7317125-B2 | Diacylglycerol acyltransferase inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2008-01-08 | — | — | US | disclosed |
| US-7317125-B2 | Diacylglycerol acyltransferase inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2008-01-08 | — | — | US | disclosed |
| US-7317125-B2 | Diacylglycerol acyltransferase inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2008-01-08 | — | — | US | disclosed |
| EP-1848687-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE (DGAT) | F. Hoffmann-Roche AG (CH) | 2007-10-31 | — | — | EP | disclosed |
| US-20060178532-A1 | Diacylglycerol acyltransferase inhibitors | VIA PHARMACEUTICALS, INC. | 2006-08-10 | — | — | US | disclosed |
| WO-2006082010-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE (DGAT) | F.HOFFMANN-LA ROCHE AG (CH) | 2006-08-10 | — | — | WO | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178532-A1 | Diacylglycerol acyltransferase inhibitors | DGAT2, DGAT1, LCAT | PKM 3251/4885SMN1; SMN2 3976/4885TSHR 2314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.